NEW PYRIDINES AS FBPASE INHIBITORS FOR TREATMENT OF DIABETES
申请人:Haap Wolfgang
公开号:US20090143439A1
公开(公告)日:2009-06-04
Compounds of formula (I)
as well as pharmaceutically acceptable salts and esters thereof wherein the residues have the significance given in claim
1
and which can be used in the form of pharmaceutical compositions.
Pyridines as FBPase inhibitors for treatment of diabetes
申请人:Hoffmann-LA Roche Inc.
公开号:US08163778B2
公开(公告)日:2012-04-24
Compounds of formula (I)
as well as pharmaceutically acceptable salts and esters thereof wherein the residues have the significance given in claim 1 and which can be used in the form of pharmaceutical compositions.
The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same. Modulators of SOS1 have the following general structure of the Formula (II),
or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein the variables are as defined herein.